| A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the … SJ Van Der Lee, OJ Conway, I Jansen, MM Carrasquillo, L Kleineidam, ... Acta neuropathologica 138, 237-250, 2019 | 110 | 2019 |
| Application of machine learning to arterial spin labeling in mild cognitive impairment and Alzheimer disease LE Collij, F Heeman, JPA Kuijer, R Ossenkoppele, MR Benedictus, ... Radiology 281 (3), 865-875, 2016 | 81 | 2016 |
| Quantification of amyloid PET for future clinical use: a state-of-the-art review HG Pemberton, LE Collij, F Heeman, A Bollack, M Shekari, G Salvadó, ... European journal of nuclear medicine and molecular imaging 49 (10), 3508-3528, 2022 | 74 | 2022 |
| Multitracer model for staging cortical amyloid deposition using PET imaging LE Collij, F Heeman, G Salvadó, S Ingala, D Altomare, A de Wilde, ... Neurology 95 (11), e1538-e1553, 2020 | 70 | 2020 |
| Assessing amyloid pathology in cognitively normal subjects using 18F-flutemetamol PET: comparing visual reads and quantitative methods LE Collij, E Konijnenberg, J Reimand, M Ten Kate, A Den Braber, IL Alves, ... Journal of Nuclear Medicine 60 (4), 541-547, 2019 | 54 | 2019 |
| Retinal layer thickness in preclinical Alzheimer's disease JA van de Kreeke, HT Nguyen, J den Haan, E Konijnenberg, J Tomassen, ... Acta ophthalmologica 97 (8), 798-804, 2019 | 53 | 2019 |
| Spatial-temporal patterns of β-amyloid accumulation: a subtype and stage inference model analysis LE Collij, G Salvadó, V Wottschel, SE Mastenbroek, P Schoenmakers, ... Neurology 98 (17), e1692-e1703, 2022 | 51 | 2022 |
| Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline JL Ebenau, W Pelkmans, IMW Verberk, SCJ Verfaillie, KA van den Bosch, ... Neurology 98 (13), e1315-e1326, 2022 | 50 | 2022 |
| The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging E Fantoni, L Collij, IL Alves, C Buckley, G Farrar Journal of Nuclear Medicine 61 (2), 166-171, 2020 | 49 | 2020 |
| AMYPAD diagnostic and patient management study: rationale and design GB Frisoni, F Barkhof, D Altomare, J Berkhof, M Boccardi, E Canzoneri, ... Alzheimer's & Dementia 15 (3), 388-399, 2019 | 43 | 2019 |
| Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study I Lopes Alves, LE Collij, D Altomare, GB Frisoni, L Saint‐Aubert, P Payoux, ... Alzheimer's & Dementia 16 (5), 750-758, 2020 | 39 | 2020 |
| Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests NR Barthélemy, G Salvadó, SE Schindler, Y He, S Janelidze, LE Collij, ... Nature medicine 30 (4), 1085-1095, 2024 | 38 | 2024 |
| Association of amyloid-β CSF/PET discordance and tau load 5 years later J Reimand, L Collij, P Scheltens, F Bouwman, R Ossenkoppele, ... Neurology 95 (19), e2648-e2657, 2020 | 38 | 2020 |
| Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent LE Collij, G Salvadó, M Shekari, I Lopes Alves, J Reimand, AM Wink, ... European journal of nuclear medicine and molecular imaging 48, 2169-2182, 2021 | 36 | 2021 |
| Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies N Mattsson-Carlgren, LE Collij, E Stomrud, AP Binette, R Ossenkoppele, ... JAMA neurology 81 (1), 69-78, 2024 | 26 | 2024 |
| White matter microstructure disruption in early stage amyloid pathology LE Collij, S Ingala, H Top, V Wottschel, KE Stickney, J Tomassen, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 13 (1 …, 2021 | 26 | 2021 |
| A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images M Bucci, I Savitcheva, G Farrar, G Salvadó, L Collij, V Doré, JD Gispert, ... European journal of nuclear medicine and molecular imaging 48, 2183-2199, 2021 | 24 | 2021 |
| Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging I Lopes Alves, F Heeman, LE Collij, G Salvadó, N Tolboom, ... Alzheimer's Research & Therapy 13, 1-13, 2021 | 21 | 2021 |
| Amyloid‐β PET and CSF in an autopsy‐confirmed cohort J Reimand, BDC Boon, LE Collij, CE Teunissen, AJM Rozemuller, ... Annals of clinical and translational neurology 7 (11), 2150-2160, 2020 | 20 | 2020 |
| Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals S Ingala, J Tomassen, LE Collij, N Prent, D van ‘t Ent, M Ten Kate, ... Brain Communications 3 (4), fcab201, 2021 | 17 | 2021 |
